Table I.

Outcome of In Vivo Treatment after Adoptive Transfer

	T15i+/+→C57BL/648 ha		T15i+/+→C57BL/696 h		T15i+/+→Fasl gld48 h
Treatment	B:Tb	Percent Δc	B:T	Percent Δ	B:T	Percent Δ
Total cells
control	0.61 ± 0.05	—	0.71 ± 0.08	—	1.2 ± 0.1d	—
SpA	0.39 ± 0.04	↓36	0.32 ± 0.04	↓54	0.6 ± 0.07	↓45
mitogen	1.7 ± 0.005	↑173	1.7 ± 0.4	↑138	2.5e	↑108
Progenitor cells
control	0.6 ± 0.05	—	NAf	—	1.3 ± 0.2	—
SpA	0.28 ± 0.04	↓54	NA	—	0.5 ± 0.09	↓57
mitogen	1.4 ± 0.08	↑133	NA	—	2.5	↑92

^aThe number of hours of in vivo exposure to SpA, OVA (control), or CpG (mitogen).

^bThe B:T ratio of isolated T15i^+/+ splenocytes was unchanged from that found in control-treated mice. In the CFSE-labeled cells, the relative loss of transferred B cells was determined after various durations in vivo using the assumption that the T cell population remains unchanged in all treatment groups. There was no evidence of T cell proliferation.

^cIndicates the percentage change, either increase (↑) or decrease (↓), compared to the control-treated group whose value is 100%.

^dAdoptive transfer of labeled T15i^+/+ splenocytes resulted in reconstitution of distinct and reproducible B:T ratios in different untreated/control-treated immunodeficient strains (unpublished data).

^eEach group contains n = 3 with this exception in which n = 1. Otherwise, mean values ± SEM are shown for each group. To estimate the number of original transferred cells (i.e., progenitor cells) that survived treatment, calculations were based on the evaluation of sequential rounds of proliferation, as previously described (reference 66), using the equation: Progenitor cells = Round 0 + (Round 1/2) + (Round 2/4) + (Round 3/8).

^fNA, not applicable as proliferation/daughter cells were not discernible.